Hypertension Evaluation and Management

Similar documents
Objectives. Describe results and implications of recent landmark hypertension trials

Hypertension Management Controversies in the Elderly Patient

Blood Pressure Targets: Where are We Now?

Management of Lipid Disorders and Hypertension: Implications of the New Guidelines

We are delighted to have Dr. Roetzheim with us today to discuss Managing Hypertension in Older Adult Patients.

What s In the New Hypertension Guidelines?

Treating Hypertension in 2018: What Makes the Most Sense Today?

Preventive Cardiology Scientific evidence

UPDATES IN AMBULATORY MEDICINE ERIK RIESSEN, MD, FACP INTERMOUNTAIN MEDICAL CENTER OUTPATIENT INTERNAL MEDICINE RESIDENCY CLINIC

가정혈압의활용 CARDIOVASCULAR CENTER. Wook Bum Pyun M.D., Ph.D. HOME BLOOD PRESSURE MONITORING. Ewha Womans University, school of Medicine

Hypertension and the SPRINT Trial: Is Lower Better

Managing Hypertension in 2018

HYPERTENSION: UPDATE 2018

No relevant financial relationships

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials

The earlier BP control the better cardiovascular outcome. Jin Oh Na Cardiovascular center Korea University Medical College

Hypertension Update Clinical Controversies Regarding Age and Race

Epidemiology and Prevention of Stroke

Dyslipidemia: Lots of Good Evidence, Less Good Interpretation.

Implementation of JNC- 8 Hypertension Recommendations: Combining evidence and value-based practice strategies for accountable care

November 9, 2018 Karen Kmetik, PhD Group Vice President, Improving Health Outcomes

Economically efficient approaches to address chronic disease in developing countries

Renal Denervation For Hypertension: Status Update

Hypertension: What s new since JNC 7. Harold M. Szerlip, MD, FACP, FCCP, FASN, FNKF

Enrollment under the Medicaid Expansion and Health Insurance Exchanges. A Focus on Those with Behavioral Health Conditions in Michigan

COSTS OF DIABETES IN DEVELOPING COUNTRIES

The Metabolic Syndrome: Is It A Valid Concept? YES

RESISTANT HYPERTENSION

Dr Diana R Holdright. MD, FRCP, FESC, FACC, MBBS, DA, BSc. Consultant Cardiologist HYPERTENSION.

Combination Therapy for Hypertension

Assessing Blood Pressure for Clinical Research: Pearls & Pitfalls

New Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.

RISE, FALL AND RESURRECTION OF RENAL DENERVATION. Michael A. Weber, MD State University of New York Downstate College of Medicine

Placebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES

Fasting or non fasting?

Egyptian Hypertension Guidelines

The Global Burden of Cardiovascular Mortality due to Sodium

Hypertension: Global Burden & Barriers

Hypertension Guidelines: International; African,?Kenyan

ADVANCES IN MANAGEMENT OF HYPERTENSION

Managing HTN in the Elderly: How Low to Go

Renal Denervation. by Walead Latif, DO, MBA, CPE Assistant Clinical Professor Rutgers Medical School

Yuqing Zhang, M.D., FESC Department of Cardiology, Fu Wai Hospital. CAMS & PUMC, Beijing, China

2018 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY. MEASURE TYPE: Process

MPharmProgramme. Hypertension (HTN)

ADVANCES IN MANAGEMENT OF HYPERTENSION

24-uur ambulante bloeddrukmeting versus thuisbloedrukmeting

4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?

Difficult-to-Control & Resistant Hypertension. Anthony Viera, MD, MPH, FAHA Professor and Chair

Blood Pressure LIMBO How Low To Go?

JNC-8. (Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure- 8) An Update on Hypertension Guidelines

Hypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute

Implications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes?

Hypertension JNC 8 (2014)

Hypertension in the Elderly. John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care

What s the evidence, why do guidelines differ, and what should the GP do?

major public health burden

New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets

Taking Charge of Your Health. Geetha Pillai, MD and Amy Emery, NP

Diversity and HTN: Approaches to optimal BP control in AfricanAmericans

The Evolution To Treatment Of Hypertension With Advanced Formulation

Placebo-Controlled Statin Trials Prevention Of CVD in Women"

lyondellbasell.com Managing Hypertension

Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center

HYPERTENSION MANAGEMENT IN ELDERLY POPULATIONS

Findings- The sample contained participants with a mean age of 55 6 years (SD 9 7), 59 5% of whom were women. 44 7% (95% CI ) of

CHRONIC DISEASE PREVALENCE AMONG ADULTS IN OHIO

Hypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B)

DIABETES. A growing problem

HYPERTENSION AND HEART FAILURE

Blood pressure treatment target in diabetes. Should it be <130 mmhg?

2/9/2017. Financial Disclosures/Unapproved Use. Achieving Harmony in Blood Pressure Guidelines Around the Globe. Roger S. Blumenthal, MD.

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process

Eliminating Barriers: Health Disparities and Solutions for African Americans

Myths, Heart Disease and the Latino Population. Maria T. Vivaldi MD MGH Women s Heart Health Program. Hispanics constitute 16.3 % of US population!

Disclosures. Hypertension: Nationwide Dilemma. Learning Objectives. What s Currently Recommended? Specific Concerns 3/9/2012

Treating Hypertension in Individuals with Diabetes

Webinar Team. University of Florida IFAS Extension. Essentials of Blood Pressure Management Series Part 1: Blood Pressure Basics

KDIGO conference on high CV risk associated with CKD. The role of BP in CKD stage 1-4

Use of Real-World Data for Population Surveillance and Monitoring. Kasia Lipska, MD Yale School of Medicine November 17 th, 2018.

Managing Hypertension in 2016

The EMPA-REG OUTCOME trial: Design and results. David Fitchett, MD University of Toronto, Canada

Prevalence, awareness, treatment and control of hypertension in North America, North Africa and Asia

Importance of Ambulatory Blood Pressure Monitoring in Adolescents

Hypertension Update 2016 AREEF ISHANI, MD MS CHIEF OF MEDICINE MINNEAPOLIS VA MEDICAL CENTER PROFESSOR OF MEDICINE UNIVERSITY OF MINNESOTA

Patrick Kay, General and Interventional Cardiologist Auckland or healthpoint.co.nz

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

T. Suithichaiyakul Cardiomed Chula

PREVER STUDY. What we learned with the PREVER-PREVENTION Trial? Dr. Sandra C. Fuchs. Professor at Universidade Federal of Rio Grande do Sul, Brazil

THE HEALTH AND ECONOMIC THREATS OF NON-COMMUNICABLE DISEASES IN THE MIDDLE EAST AND NORTH AFRICA, CV BoD in Egypt/ MENA

Diabetes Mellitus: A Cardiovascular Disease

Meeting the 2025 salt and raised blood pressure reduction targets

4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for

Blood Pressure Measurement in SPRINT

Συμπεράσματα από τις νέες μελέτες για την αρτηριακή υπέρταση (SPRINT,PATHAY 2,HOPE 3)

Contribution of NCD and CVD to the Global Mortality and GBD in 1998 (LIC & MIC)

Placebo-Controlled Statin Trials

Intervention: Hypertension

Hypertension and Cholesterol in the Elderly

Disclosure. I have no relevant financial relationships with commercial interests to disclose American Medical Association. All rights reserved.

Transcription:

Hypertension Evaluation and Management ü Identify High Blood Pressure ü Reduce Salt ü Personalize BP Target Erica S. Spatz, MD, MHS Assistant Professor, Cardiovascular Medicine Center for Outcomes Research and Evaluation Yale University School of Medicine

Disclosures Develop outcome measures under a contract with the Centers for Medicare and Medicaid Services (CMS) NIH/NIMHD funded U54. Project Lead: Health Disparities in Hypertension: A Precision Medicine-based Approach for Early Risk Stratification

Hypertension: The Silent Killer

Hypertension: A Global Health Crisis 29% 26% 45% Forouzanfar MH, JAMA. 2017

Higher burden of stroke in low and middle income regions. HTN accounted for 14% of deaths (>10 million) & >212 million DALYs in 2015 1.4-fold increase since 1990 Forouzanfar MH, JAMA. 2017

China: Million Persons Project Overall, ½ of adults aged 35 to 75 had HTN Only 1/3 were treated 1 in 12 were controlled (<140/90) Lu J, Lu Y. Lancet.,2017

HTN in the US: A Tale of 2 Cities Manhattan and Brooklyn Heights, HTN rates of 16-25% Bronx and other parts of Brooklyn, HTN rates of 30-40%

US Hypertension Prevalence RACE 18 and Over Age-Adjusted Prevalence 29% White 28% Black 42% INCOME 25 and Over <100% FPL 100-300% FPL >300% FPL 50.8% 50.8% 40.3% FPL: Federal Poverty Level Hispanic 26% Asian 25% Beckman AL Spatz ES. JAMA Cardiology, 2017; Wang YC...Schwartz JE Am J Epidemiol, 2017

The problem is likely much worse. Other phenotypes of hypertension, typically not measured, also portend worse cardiovascular outcomes.

Evaluation: Phenotypes of HTN HTN Masked HTN Nocturnal Non- Dipping Wang YC...Schwartz JE Am J Epidemiol, 2017

Masked HTN NIMHD Precision Medicine Grant: ABPM Trajectory Phenotypes

ACC/AHA 2017 Guidelines

ACC/AHA 2017 Guidelines

Evaluation Summary Personalized, Population Health Approach Engage persons inside and outside of the medical setting Focused screening: populations at risk; families; networks Attention to contextual environment Diagnosis of HTN Home-based monitoring 24-hour ABPM Develop cheap, convenient BP detection devices

Hypertension Management To reach BP goal of 120/80 mmhg and to improve cardiovascular outcomes?

A Global Taste of Salt Intake Salt intake is high across the globe. N America 4-5 g/d of sodium (goal <2.3 g/d) Central, Asian Pacific, East Asia, and Eastern Europe have the highest salt intake Powles, J et al. BMJ Open. 2013

Will lowering salt reduce CV risk? Population Level Individual Level We eat too much salt. Lower sodium intake is associated with lower blood pressure and fewer cardiovascular events At an individual level, yes in some populations, though its difficult and the benefits are less certain. Menta A (PURE); O Donnell MJ (PURE), Mozaffarian D, (NutriCode). NEJM, 2014

Salt Reduction: Challenge The issue is not what you do with your salt shaker. --David Katz, MD Yale University Preventive Medicine

Salt Reduction: Individual Level

Personalized Approach

Individualize based on risk ü Personal evidence of target organ damage ü Family hx of stroke, CAD, blindness or renal disease

Individualize based on risk SPRINT ACCORD HOPE 3 Goal Treat to Target Treat to Target Fixed dose med trial Strategy tested <140 vs <120 <140 vs <120 ARB/thiazide v. placebo In whom? High risk patients Diabetes Intermediate risk What worked? <120 mmhg <140 mmhg <140 mmhg At what expense? At what benefit? ++ meds ++ side effects resulting in ED visits 25% RRR in MACE, (no reduction in MI or stroke) More side effects (renal) No difference in MACE or death. Fewer strokes. No difference in discontinuation (25% both arms) Benefit restricted to group with systolic BP >142 mmhg

Shared Decision Making Personalize identification and characterization of BP patterns Assess BP in context of overall CV risk Co-design goals Find therapies with the least burden Manage contributors to hypertension lifestyle, stress Openly address adherence

A person-centered approach takes a health system Assess Risk Factors ü Diet ü Physical Activity ü Stress ü Weight ü Social context ü Physical env ü SES ü Access to care ü Out of pocket costs Health Promotion ü Personalize diagnosis ü Elicit preferences and goals ü Do shared decision making ü Improve health system support ü Continued feedback and realignment